Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2014 (2014), Article ID 439146, 18 pages
http://dx.doi.org/10.1155/2014/439146
Research Article

Synergistic Antiproliferative Effects of Combined γ-Tocotrienol and PPARγ Antagonist Treatment Are Mediated through PPARγ-Independent Mechanisms in Breast Cancer Cells

College of Pharmacy, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209, USA

Received 22 November 2013; Accepted 23 January 2014; Published 4 March 2014

Academic Editor: Richard P. Phipps

Copyright © 2014 Abhita Malaviya and Paul W. Sylvester. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. S. McIntyre, K. P. Briski, M. A. Tirmenstein, M. W. Fariss, A. Gapor, and P. W. Sylvester, “Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells,” Lipids, vol. 35, no. 2, pp. 171–180, 2000. View at Google Scholar · View at Scopus
  2. B. S. Mcintyre, K. P. Briski, A. Gapor, and P. W. Sylvester, “Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells,” Experimental Biology and Medicine, vol. 224, no. 4, pp. 292–301, 2000. View at Google Scholar · View at Scopus
  3. C. Schneider, “Chemistry and biology of vitamin E,” Molecular Nutrition & Food Research, vol. 49, pp. 7–30, 2005. View at Google Scholar
  4. P. W. Sylvester and S. J. Shah, “Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells,” Frontiers in Bioscience, vol. 10, pp. 699–709, 2005. View at Google Scholar · View at Scopus
  5. G. V. Samant and P. W. Sylvester, “γ-tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells,” Cell Proliferation, vol. 39, no. 6, pp. 563–574, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. V. Bachawal, V. B. Wali, and P. W. Sylvester, “Enhanced antiproliferative and apoptotic response to combined treatment of γ-tocotrienol with erlotinib or gefitinib in mammary tumor cells,” BMC Cancer, vol. 10, article 84, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Fang, Z. Kang, and C. Wong, “Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors,” Molecular Nutrition and Food Research, vol. 54, no. 3, pp. 345–352, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. E. Campbell, B. Rudder, R. B. Phillips et al., “γ-tocotrienol induces growth arrest through a novel pathway with TGFβ2 in prostate cancer,” Free Radical Biology and Medicine, vol. 50, no. 10, pp. 1344–1354, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Malaviya and P. W. Sylvester, “Mechanisms mediating the effects of gamma-tocotrienol when used in combination with PPARgamma agonists or antagonists on MCF-7 and MDA-MB-231 breast cancer cells,” International Journal of Breast Cancer, vol. 2013, Article ID 101705, 2013. View at Publisher · View at Google Scholar
  10. E. D. Rosen and B. M. Spiegelman, “PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth,” Journal of Biological Chemistry, vol. 276, no. 41, pp. 37731–37734, 2001. View at Google Scholar · View at Scopus
  11. W. Wahli, O. Braissant, and B. Desvergne, “Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more,” Chemistry and Biology, vol. 2, no. 5, pp. 261–266, 1995. View at Publisher · View at Google Scholar · View at Scopus
  12. S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, “A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation,” Cell, vol. 83, no. 5, pp. 813–819, 1995. View at Google Scholar · View at Scopus
  13. B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-Δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ,” Cell, vol. 83, no. 5, pp. 803–812, 1995. View at Google Scholar · View at Scopus
  14. Y. Urade and N. Eguchi, “Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence,” Prostaglandins and Other Lipid Mediators, vol. 68-69, pp. 375–382, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Chinery, R. J. Coffey, R. Graves-Deal et al., “Prostaglandin J2 and 15-deoxy-Δ12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells,” Cancer Research, vol. 59, no. 11, pp. 2739–2746, 1999. View at Google Scholar · View at Scopus
  16. A. F. Badawi and M. Z. Badr, “Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review),” International Journal of Oncology, vol. 20, no. 6, pp. 1109–1122, 2002. View at Google Scholar · View at Scopus
  17. A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, “PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation,” Nature Medicine, vol. 7, no. 1, pp. 48–52, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Eibl, “The role of PPAR-γ and its interaction with COX-2 in pancreatic cancer,” PPAR Research, vol. 2008, Article ID 326915, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. C. E. Clay, A. Monjazeb, J. Thorburn, F. H. Chilton, and K. P. High, “15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells,” Journal of Lipid Research, vol. 43, no. 11, pp. 1818–1828, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Li and H. Narahara, “15-deoxy-delta(12,14)-prostaglandin J(2) induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer cell lines,” International Journal of Molecular Medicine, vol. 31, pp. 778–788, 2013. View at Google Scholar
  21. S.-J. Wu, P.-L. Liu, and L.-T. Ng, “Tocotrienol-rich fraction of palm oil exhibits anti-inflammatory property by suppressing the expression of inflammatory mediators in human monocytic cells,” Molecular Nutrition and Food Research, vol. 52, no. 8, pp. 921–929, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. B. Shirode and P. W. Sylvester, “Synergistic anticancer effects of combined γ-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFκB signaling,” Biomedicine and Pharmacotherapy, vol. 64, no. 5, pp. 327–332, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. A. B. Shirode and P. W. Sylvester, “Mechanisms mediating the synergistic anticancer effects of combined γ-tocotrienol and celecoxib treatment,” Journal of Bioanalysis and Biomedicine, vol. 3, no. 1, pp. 1–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Y. Zaytseva, N. K. Wallis, R. C. Southard, and M. W. Kilgore, “The PPARγ antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARγ-dependent and -independent mechanisms,” Anticancer Research, vol. 31, no. 3, pp. 813–823, 2011. View at Google Scholar · View at Scopus
  25. S. Sikka, L. Chen, G. Sethi, and A. P. Kumar, “Targeting PPARgamma signaling cascade for the prevention and treatment of prostate cancer,” PPAR Research, vol. 2012, Article ID 968040, 14 pages, 2012. View at Publisher · View at Google Scholar
  26. L. W. Anderson, K. G. Danielson, and H. L. Hosick, “New cell line. Epithelial cell line and subline established from premalignant mouse mammary tissue,” In Vitro, vol. 15, no. 11, pp. 841–843, 1979. View at Google Scholar · View at Scopus
  27. K. G. Danielson, L. W. Anderson, and H. L. Hosick, “Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo,” Cancer Research, vol. 40, no. 6, pp. 1812–1819, 1980. View at Google Scholar · View at Scopus
  28. U. K. Laemmli, “Cleavage of structural proteins during the assembly of the head of bacteriophage T4,” Nature, vol. 227, no. 5259, pp. 680–685, 1970. View at Publisher · View at Google Scholar · View at Scopus
  29. P. W. Sylvester, H. P. Birkenfeld, H. L. Hosick, and K. P. Briski, “Fatty acid modulation of epidermal growth factor-induced mouse mammary epithelial cell proliferation in vitro,” Experimental Cell Research, vol. 214, no. 1, pp. 145–153, 1994. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Towbin, T. Staehelin, and J. Gordon, “Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 9, pp. 4350–4354, 1979. View at Google Scholar · View at Scopus
  31. H.-H. Kim, U. Vijapurkar, N. J. Hellyer, D. Bravo, and J. G. Koland, “Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein,” Biochemical Journal, vol. 334, no. 1, part 1, pp. 189–195, 1998. View at Google Scholar · View at Scopus
  32. R. J. Tallarida, “Drug synergism: its detection and applications,” Journal of Pharmacology and Experimental Therapeutics, vol. 298, no. 3, pp. 865–872, 2001. View at Google Scholar · View at Scopus
  33. D. Shen, C. Deng, and M. Zhang, “Peroxisome proliferator-activated receptor γ agonists inhibit the proliferation and invasion of human colon cancer cells,” Postgraduate Medical Journal, vol. 83, no. 980, pp. 414–419, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. P. W. Sylvester, V. B. Wali, S. V. Bachawal, A. B. Shirode, N. M. Ayoub, and M. R. Akl, “Tocotrienol combination therapy results in synergistic anticancer response,” Frontiers in Bioscience, vol. 16, no. 7, pp. 3183–3195, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Nesaretnam, N. Guthrie, A. F. Chambers, and K. K. Carroll, “Effect of tocotrienols on the growth of a human breast cancer cell line in culture,” Lipids, vol. 30, no. 12, pp. 1139–1143, 1995. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Nesaretnam, R. Stephen, R. Dils, and P. Darbre, “Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status,” Lipids, vol. 33, no. 5, pp. 461–469, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. X. Wang, R. C. Southard, and M. W. Kilgore, “The increased expression of peroxisome proliferator-activated receptor-γ1 in human breast cancer is mediated by selective promoter usage,” Cancer Research, vol. 64, no. 16, pp. 5592–5596, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Y. Zaytseva, X. Wang, R. C. Southard, N. K. Wallis, and M. W. Kilgore, “Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells,” Molecular Cancer, vol. 7, article 90, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Subbarayan, X.-C. Xu, J. Kim et al., “Inverse relationship between 15-lipoxygenase-2 and PPAR-γ gene expression in normal epithelia compared with tumor epithelia,” Neoplasia, vol. 7, no. 3, pp. 280–293, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. M. A. Lea, M. Sura, and C. Desbordes, “Inhibition of cell proliferation by potential Peroxisome Proliferator-Activated Receptor (PPAR) gamma agonists and antagonists,” Anticancer Research, vol. 24, no. 5, pp. 2765–2771, 2004. View at Google Scholar · View at Scopus
  41. J. D. Burton, D. M. Goldenberg, and R. D. Blumenthal, “Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types,” PPAR Research, vol. 2008, Article ID 494161, 7 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. J. K. Reddy, N. Viswakarma, Y. Jia et al., “Coactivators in PPAR-regulated gene expression,” PPAR Research, vol. 2010, Article ID 250126, 21 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Uefuji, T. Ichikura, and H. Mochizuki, “Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas,” Journal of Surgical Oncology, vol. 76, pp. 26–30, 2001. View at Google Scholar
  44. O. N. Tucker, A. J. Dannenberg, E. K. Yang et al., “Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer,” Cancer Research, vol. 59, no. 5, pp. 987–990, 1999. View at Google Scholar · View at Scopus
  45. S. Kulkarni, J. S. Rader, F. Zhang et al., “Cyclooxygenase-2 is overexpressed in human cervical cancer,” Clinical Cancer Research, vol. 7, no. 2, pp. 429–434, 2001. View at Google Scholar · View at Scopus
  46. N. M. Davies and F. Jamali, “COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 3, pp. 332–336, 2004. View at Google Scholar · View at Scopus
  47. K. Fujimori, K. Aritake, and Y. Urade, “Enhancement of prostaglandin D2 production through cyclooxygenase-2 and lipocalin-type prostaglandin D synthase by upstream stimulatory factor 1 in human brain-derived TE671 cells under serum starvation,” Gene, vol. 426, no. 1-2, pp. 72–80, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. C. P. Masamha and D. M. Benbrook, “Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells,” Cancer Research, vol. 69, no. 16, pp. 6565–6572, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. G. V. Samant, V. B. Wali, and P. W. Sylvester, “Anti-proliferative effects of γ-tocotrienol on mammary tumour cells are associated with suppression of cell cycle progression,” Cell Proliferation, vol. 43, no. 1, pp. 77–83, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. J.-R. Weng, C.-Y. Chen, J. J. Pinzone, M. D. Ringel, and C.-S. Chen, “Beyond peroxisome proliferator-activated receptor γ signaling: the multi-facets of the antitumor effect of thiazolidinediones,” Endocrine-Related Cancer, vol. 13, no. 2, pp. 401–413, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Suzuki, K. Sato, N. Yoshizumi, and I. Nishiya, “Inhibition of growth of human endometrial adenocarcinoma cells in vitro treated with prostaglandin F2 alpha, E2, D2 and J2,” Nippon Naibunpi Gakkai zasshi, vol. 62, no. 8, pp. 857–866, 1986. View at Google Scholar · View at Scopus
  52. T. Yoshida, S. Ohki, M. Kanazawa et al., “Inhibitory effects of prostaglandin D2 against the proliferation of human colon cancer cell lines and hepatic metastasis from colorectal cancer,” Surgery Today, vol. 28, no. 7, pp. 740–745, 1998. View at Publisher · View at Google Scholar · View at Scopus
  53. J. U. Scher and M. H. Pillinger, “15d-PGJ2: the anti-inflammatory prostaglandin?” Clinical Immunology, vol. 114, no. 2, pp. 100–109, 2005. View at Publisher · View at Google Scholar · View at Scopus